Related Experiment Videos
Termination and suppression of idiopathic left ventricular tachycardia by diltiazem
1Department of Medicine, University of Florida, Gainesville 32610, USA.
Insights
Diltiazem effectively terminates and suppresses idiopathic left ventricular tachycardia (ILVT). This calcium-channel blocker offers a potential treatment option for both acute and long-term management of ILVT in patients with structurally normal hearts.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Idiopathic left ventricular tachycardia (ILVT) is a recognized clinical entity.
- Verapamil is a known treatment for many cases of ILVT.
- The efficacy of other calcium-channel blockers, like diltiazem, for ILVT remains largely uninvestigated.
Observation:
- A case of ILVT in a patient with a structurally normal heart is presented.
- Intravenous diltiazem successfully terminated the tachycardia in an electrophysiology laboratory setting.
- Sustained-release oral diltiazem provided long-term suppression of the arrhythmia.
Findings:
- A single intravenous dose of diltiazem acutely terminated idiopathic left ventricular tachycardia.
- Long-term administration of sustained-release diltiazem suppressed recurrent episodes of ILVT.
- Diltiazem demonstrates efficacy in both acute and chronic management of ILVT.
Implications:
- Diltiazem represents a viable therapeutic option for idiopathic left ventricular tachycardia.
- This finding expands treatment possibilities beyond verapamil for ILVT.
- Further research into diltiazem's role in ILVT management is warranted.
Abstract:
Idiopathic left ventricular tachycardia is known to be responsive to verapamil in many cases. However, the role of other calcium-channel blockers, such as diltiazem, in treating this specific type of ventricular tachycardia is unknown. We report a case of idiopathic left ventricular tachycardia in a patient with a structurally normal heart, which was terminated and suppressed in the electrophysiology laboratory by a single dose of diltiazem intravenously, and was subsequently suppressed long-term with sustained-release diltiazem. Our finding suggests that idiopathic left ventricular tachycardia may be managed effectively with diltiazem in both the acute and chronic settings.